Brain cancer breakthrough? new device zaps tumors during surgery

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The subject's age must be ≥ 40 years but not older than 75 years. * The subject's Karnofsky Performance Status (KPS) must be ≥ 70%. * The subject is willing and able to independently provide informed consent for participation in the study. * The subject has been newly diagnosed with glioblastoma (GB) based on preoperative neuroimaging (contrast-enhanced brain MRI ± amino acid-based PET/CT) and confirmed by intraoperative histopathological examination of the tumor. * Total or near-total resection of the contrast-enhancing tumor portion is feasible. * The expected post-resection cavity size must allow placement of the Axxent Xoft eBx balloon applicator system. * Women of childbearing potential must have a negative pregnancy test within 7 days before treatment initiation. * The subject must have a complete blood count (CBC) with or without differential within 7 days before study enrollment, demonstrating adequate bone marrow function: * Absolute neutrophil count (ANC) ≥ 1500 cells/mm³ * Platelets ≥ 75,000 cells/mm³ * Hemoglobin ≥ 10.0 g/dL * The subject must undergo kidney and liver function tests within 7 days before study enrollment, with the following required parameters: * Total bilirubin ≤ 2.0 mg/dL, and AST ≤ 2.5 × upper limit of normal (ULN) * Serum creatinine ≤ 1.8 mg/dL within 14 days before enrollment. * The subject's urine protein levels must meet the following criteria within 14 days before enrollment: * Urine protein-to-creatinine ratio (UPCR) \< 1.0, OR * Dipstick urinalysis ≤ 2+ proteinuria (if \> 2+, a 24-hour urine collection must show ≤ 1 g protein/24h). * Patients on anticoagulant therapy (e.g., warfarin or low-molecular-weight heparin) must meet all of the following: * No active bleeding or high-risk bleeding conditions (e.g., tumor involving major vessels or varices). * Stable INR (typically 2-3) on oral anticoagulants OR stable dose of LMWH for ≥ 14 days before enrollment. Exclusion Criteria: * Multicentric/multifocal glioblastoma growth. * Infratentorial or leptomeningeal tumor spread. * Recurrent/progressive glioblastoma. * Prior cranial radiation therapy. * Glioblastoma located in or near (≤ 10 mm from) critical brain structures, preventing adequate radiation dose delivery. * Contrast-enhancing tumor diameter \> 6 cm. * Active or prior malignancy (except adequately treated non-melanoma skin cancer or carcinoma in situ). * Other intracranial neoplasms (current or history). * Pregnancy, lactation, or unwillingness to use effective contraception (for women of childbearing potential or sexually active men). * Contraindications to MRI (with or without gadolinium). * Non-removable or clinically inoperable cardiac pacemaker/device. * Contraindications to general anesthesia. * Concurrent participation in another clinical trial. * Severe comorbidities, including: * Unstable angina or congestive heart failure requiring hospitalization (within 6 months). * Transmural myocardial infarction (within 6 months). * Stroke or transient ischemic attack (within 6 months). * Significant vascular disease (aortic/peripheral). * Active venous/arterial thromboembolism. * Acute bacterial/fungal infection requiring IV antibiotics. * COPD exacerbation or respiratory disease interfering with protocol therapy. * Liver failure causing jaundice/coagulopathy. * Positive serology for HIV, HBV, HCV, or syphilis. * Grade ≥ 3 hemorrhage (CTCAE v5.0) within 30 days before enrollment.